India Caps Anti-Cancer Drug Trade Margin at 30%
Government caps trade margins on non-scheduled anti-cancer drugs at 30% to improve affordability and reduce patient financial distress.
In a major move to make life-saving treatments more accessible, the Government of India has decided to cap the trade margins on non-scheduled anti-cancer drugs at 30%. This decision aims to reduce the heavy financial burden placed on cancer patients and their families across the country.
Industry and Experts Welcome the Move
The Indian Pharmaceutical Alliance (IPA) has hailed the announcement of trade margin rationalisation for cancer medicines as a "welcome step." According to the IPA, while Indian companies play a vital role in providing quality-assured and affordable medicines at some of the lowest prices globally, this new cap represents a balanced approach. It seeks to prioritize patient welfare while ensuring that channel members still receive adequate margins to maintain the supply chain.
Nikkhil K Masurkar, CEO of ENTOD Pharmaceuticals, described the decision as patient-centric. He noted that excessive trade margins on life-saving medicines have long contributed to the financial distress faced by families. "Rationalising these margins without affecting manufacturers’ revenues is a balanced approach that protects patient interests while supporting the pharma industry," Masurkar stated.
Impact on Patient Care and Treatment Adherence
Medical professionals believe this policy could fundamentally change how cancer care is delivered in India. By lowering the cost of drugs, the government aims to prevent "treatment abandonment," a situation where patients are forced to stop life-saving medication due to lack of funds.
Dr. MD Ray, a Surgical Oncologist at AIIMS Delhi, welcomed the proposed cap, noting that lower prices could significantly improve access to both preoperative and postoperative systemic therapy. However, he cautioned that a price reduction of "up to 70%" is not a universal guarantee and emphasized that implementation must ensure uninterrupted supply and quality.
The Need for Effective Implementation
While the potential for savings is high, experts stress that the benefit must reach the patient at the pharmacy counter. Dr. Abhishek Shankar, Assistant Professor of Radiation Oncology at AIIMS Delhi, highlighted that for many families, medicine costs can determine whether a patient continues treatment or is forced to compromise.
Dr. Shankar noted that to translate this policy into real-world benefits, the following elements are essential:
- Effective implementation of the margin cap.
- Transparent pricing mechanisms.
- Regular monitoring of market rates.
- Uninterrupted availability of high-quality medicines.
"Cancer treatment should be guided by clinical need, not by a family’s ability to pay," Dr. Shankar added, underscoring the importance of making affordability a reality at the patient's bedside.